CommercialDocumentationMedium impact
08.00.33t, Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.33t has been updated with changes to medical necessity criteria and medical coding for Trastuzumab (Herceptin®), related biosimilars, and Trastuzumab with Hyaluronidase-oysk (Herceptin Hylecta). The billing team must review and implement updated coding and medical necessity documentation requirements effective immediately.
Action Required
By June 16, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-33t to identify specific billing codes affected and medical necessity criteria changes. Update billing software, encounter templates, and provider documentation requirements to reflect new medical necessity criteria. Coordinate with oncology providers to ensure claims include required clinical documentation. Failure to comply may result in claim denials or payment delays for Herceptin-related therapies.